Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00338286 · ClinicalTrials.gov registry record · Phase 3
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,098
- Enrollment target
NCT00338286 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 2,098 participants.
The verdict
NCT00338286, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,098 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the impact on tumor progression as evaluated by progression-free survival (PFS) of epoetin alfa plus standard supportive care as compared with standard supportive care alone (packed red blood cell (RBC) transfusions), for treating anemia according to label guidance in patients with metastatic breast cancer receiving standard chemotherapy.
Interventions
- OTHER Standard supportive care (packed RBC transfusion)
- DRUG epoetin alfa + packed RBC transfusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,098 participants |
| Start Date | 2006-03-02 |
| Est. Completion | 2017-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00338286
The ClinicalTrials.gov registry entry for NCT00338286 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,098 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard supportive care (packed RBC transfusion) is the first listed.
NCT00338286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00338286 about?
NCT00338286 is a clinical study titled "A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy". The purpose of this study is to assess the impact on tumor progression as evaluated by progression-free survival (PFS) of epoetin alfa plus standard supportive care as compared with standard supportive care alone (packed red blood cell (RBC) transfusions), for treating anemia according to label guid...
What is the current status of trial NCT00338286?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,098 participants. The study started on 2006-03-02. Estimated completion is 2017-01-31.
What interventions are being tested in trial NCT00338286?
The interventions under investigation include: Standard supportive care (packed RBC transfusion) (OTHER), epoetin alfa + packed RBC transfusion (DRUG).
Who is sponsoring clinical trial NCT00338286?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.